Vapen has some actual profits to report, a respectable list of in-demand products and now that they’ve coined their first patent (which we’ll get to) they’ve dug the first opening trenches in a moat around their product line, which was something they had been lacking previously.
The company announced today that they have been granted a patent for their metered dose inhaler from the United States Patent and Trademark office.
The patent covers advancements to their THC and CBD inhaler, which now uses a propellant to atomize the chemical without heat for easier access to the lungs. That means a smoother inhalation experience for users, and a patent to leverage against anyone else building something similar.
“We are very satisfied with the scope of this patent covering the device, the delivered content, and the use of a propellant, all key elements that enable this safe and convenient inhaler to give customers simply the best way to get a precise and measured dose. This broad utility patent brings tremendous value to our Company and our brand, as well as new opportunities to drive sales, expand our market presence, and increase shareholder value,” said Thai Nguyen, Founder and Chief Executive Officer of Vapen MJ Ventures.
Let’s not get ahead of ourselves here, though.
The patent’s neat, but the market for cannabis delivery systems is full of options.
People who smoke cannabis have an increased risk of acquiring asthma, lung diseases, various types of cancers and other assorted respiratory diseases. For folks who don’t want to court these diseases, or maybe find the burning lung sensation from smoking cannabis uncomfortable, there’s always sublingual strips, topical applications for the skin, and transdermal patches. Vaping is another option, although there’s been some recent reports about potential health complications including lung damage.
Vapen’s inhalers offer a safe, easy-to-use alternative to smoking or using edibles to consume THC or CBD products. No burning lung and no health complications. The inhaler offers a pressurized, metered 10 milligram (mg) dose of pharmaceutical grade THC or CBD isolate.
The utility patent consists of:
- an inhaler system consisting of an actuator,
- a user interchangeable canister assembly,
- purified cannabinoid from cannabis
- isolated terpene
- hydrofluorocarbon propellant
The patent will be valid until 2038. Vapen also has an unpublished patent pending for some additional claims on the inhaler system.
Everyone knows what asthma is. It’s a chronic, long-term inflammatory lung disease that affects the airways. It’s inheritable, and one of the many environmental prices we pay for living in the modern world.
- 40,000 people miss school or work due to asthma.
- 30,000 people have an asthma attack.
- 5,000 people visit the emergency room due to asthma.
- 1,000 people are admitted to the hospital due to asthma.
- 11 people die from asthma.
There’s an important distinction to make here regarding cannabis and asthma: THC and CBD do not cause asthma attacks. If someone’s ingesting cannabis and they get an asthma attack, it’s the delivery system that’s at fault. They’re probably smoking it, or vaping it, and the harshness from the smoke is irritating the delicate tissues in their lungs.
But there are studies confirming that cannabis ingestion using an inhaler actually works to ease the strain on the bronchial tubes, acting as a bronchodilator, or a substance and dilates the bronchi and bronchioles, which decrease the resistance in the respiratory airway and increase airflow to the lungs.
That’s a $0.30 rise on actual profits. Re-read that sentence. Actual profits.
Finally, something worth celebrating about in cannabis.
Full disclosure: Vapen MJ Ventures is an equity.guru marketing client.